We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER...
83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free survival (PFS) of 4.1 months in ADC...
PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MDTwo poster presentations include Drs. Hurvitz (Fred Hutchinson Cancer Center), Brufsky (UPMC), and...
Preclinical data shows that BriaCell’s Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic...
PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice that of controls in similar studies PFS results reinforced by larger number of prior...
Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized...
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) a clinical-stage immunotherapy company driven to fight cancer and improve patients’ lives, announced that it has received approval To...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.3 | -13.6363636364 | 2.2 | 2.2 | 1.77 | 16813 | 2.00468726 | CS |
4 | -1.04 | -35.3741496599 | 2.94 | 3.27 | 1.77 | 11156 | 2.08497674 | CS |
12 | -2.6 | -57.7777777778 | 4.5 | 4.59 | 1.77 | 11563 | 3.12625556 | CS |
26 | -4.82 | -71.7261904762 | 6.72 | 8 | 1.77 | 7997 | 4.0031934 | CS |
52 | -6.26 | -76.7156862745 | 8.16 | 10.29 | 1.77 | 5741 | 5.23714019 | CS |
156 | -8.94 | -82.4723247232 | 10.84 | 15.05 | 1.77 | 7479 | 7.89751979 | CS |
260 | -8.94 | -82.4723247232 | 10.84 | 15.05 | 1.77 | 7479 | 7.89751979 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions